SAN reports Phase IIb limb ischemia data

sanofi-aventis (Euronext:SAN; SNY) said its NV1FGF ( XRP0038) missed the primary endpoint of incidence of ulcer healing in the Phase IIb TALISMAN 201 trial to treat critical limb ischemia. However, in...